샘플 요청 목록

 카트 문의
시장보고서
상품코드
1758161

세계의 당뇨병성 케톤산증 시장

Diabetic Ketoacidosis
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 279 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 당뇨병성 케톤산증 시장은 2030년까지 38억 달러에 달할 전망

2024년에 31억 달러로 추정되는 세계의 당뇨병성 케톤산증 시장은 2024-2030년의 분석 기간에 CAGR 3.4%로 성장하며, 2030년에는 38억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 인슐린 치료제는 CAGR 2.9%를 기록하며, 분석 기간 종료시에는 20억 달러에 달할 것으로 예측됩니다. 전해질 보충 치료 부문의 성장률은 분석 기간 중 CAGR 3.8%로 추정됩니다.

미국 시장은 8억 5,630만 달러로 추정, 중국은 CAGR 6.2%로 성장 예측

미국의 당뇨병성 케톤산증 시장은 2024년에 8억 5,630만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 분석 기간인 2024-2030년의 CAGR 6.2%를 견인하는 형태로, 2030년까지 7억 5,660만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 1.3%와 2.6%로 예측됩니다. 유럽에서는 독일이 CAGR 1.9%로 성장할 것으로 예측됩니다.

세계의 당뇨병성 케톤산증 치료제 시장 - 주요 동향과 촉진요인 정리

당뇨병성 케톤산증이 당뇨병 치료에서 점점 더 중요한 초점이 되고 있는 이유는 무엇인가?

당뇨병성 케톤산증(DKA)은 생명을 위협하는 심각한 당뇨병의 급성 합병증으로, 주로 1형 당뇨병 환자 및 최근에는 잘 관리되지 않는 2형 당뇨병 환자가 앓고 있으며, 인슐린 결핍으로 인해 발생하여 지방의 과분해, 케톤체 생성 및 대사성 산증을 유발합니다. DKA는 인슐린 투여 누락, 감염, 외상 또는 당뇨병의 미진단으로 인해 발생하는 경우가 많으며, 치료하지 않으면 혼수상태에 빠지거나 사망에 달할 수 있습니다. 전 세계에서 당뇨병 유병률이 증가함에 따라 특히 젊은 연령층과 치료받지 못하는 사람들이 증가함에 따라 DKA 에피소드의 빈도와 의료비 부담도 증가하고 있습니다.

인슐린 의존성 환자 증가와 더불어, 중저소득 국가에서는 지속적인 혈당 모니터링과 적시에 개입할 수 있는 접근성이 제한되어 있으며, DKA 관리는 당뇨병의 응급 및 만성 치료에서 최우선 과제가 되고 있습니다. 또한 2형 당뇨병에서 SGLT2 억제제의 사용이 증가함에 따라 뚜렷한 고혈당 없이 케톤산증이 발생하는 '고혈당성 DKA'의 위험이 증가하여 조기 발견과 감별이 더욱 어려워지고 있습니다. 이러한 위험 프로파일의 변화로 인해 의료기관은 입원 및 외래 환자를 대상으로 보다 광범위한 스크리닝 및 치료 프로토콜을 도입해야 할 필요성이 대두되고 있습니다.

DKA를 관리하기 위한 주요 치료 전략과 임상 프로토콜은 무엇인가?

DKA의 치료는 정맥 인슐린 주입, 수액 소생술, 전해질 보정(특히 칼륨), 근본적인 유발 요인의 식별 및 해결을 포함한 확립된 프로토콜을 중심으로합니다. 등장성 식염수의 즉각적인 투여는 순환량 회복에 도움이 되며, 인슐린 요법은 케톤 생성을 중단하고 고혈당을 점진적으로 감소시킵니다. 인슐린 요법은 칼륨을 세포 내로 흡수하므로 주의 깊게 모니터링하지 않으면 종종 위험한 저칼륨혈증으로 이어질 수 있으므로 칼륨 보충이 매우 중요합니다. 심각한 경우 중탄산염 요법은 심한 산증을 교정하기 위해 중탄산염 요법을 사용할 수 있지만, 그 사용은 극도의 pH 이상이 있는 경우에만 제한됩니다.

침상에서의 신속한 혈중 케톤 측정, 동맥혈 가스 분석, 혈당 및 전해질 수준의 지속적인 모니터링은 급성 DKA 관리에 필수적인 요소입니다. 병원 응급실과 중환자실은 일반적으로 중등도에서 중증의 DKA 환자를 분류하고 안정화시키기 위한 프로토콜을 갖추고 있습니다. 회복 후 환자는 재발 방지를 위해 구조화된 인슐린 요법 조정, 아픈 날 규칙에 대한 교육, 포도당 모니터링에 대한 접근성 개선이 필요합니다. 이러한 전신적 접근을 위해서는 내분비 전문의, 응급의료 프로바이더, 당뇨병 교육자, 중증 치료 전문의의 협력이 필요합니다.

기술 및 진단의 발전이 DKA 관리 및 예방을 어떻게 강화하고 있는가?

당뇨병 치료의 기술 혁신은 DKA의 조기 발견과 관리를 크게 향상시키고 있습니다. 연속 혈당 모니터링(CGM) 시스템, 자동 서스펜션 기능이 있는 인슐린 펌프, 실시간 알림 기능이 있는 모바일 앱은 환자가 심각한 탈혈이 발생하기 전에 대사 변화를 발견할 수 있도록 돕고 있습니다. 혈중 케톤 측정기는 현재 가정용으로 널리 보급되어 질병이나 인슐린 중단시 조기 진단이 가능해져 입원 및 장기 합병증을 줄일 수 있게 되었습니다.

의료 서비스 프로바이더들은 전자건강기록의 예측 분석을 활용하여 DKA 위험이 높은 환자, 특히 감염, 수술, 약물 불이동으로 인한 입원 중 DKA 위험이 높은 환자들을 찾아내는 데 활용하고 있습니다. 원격의료 서비스와 통합된 교육 플랫폼은 인슐린 순응도, 영양 계획, 질병 발생시 조기 개입을 지원함으로써 DKA를 예방하는 데 중요한 역할을 하고 있습니다. 원격 당뇨병 관리와 구조화된 퇴원 계획의 확대는 환자의 장기적인 결과를 개선하고 재발률을 낮추고 있습니다.

당뇨병성 케톤산증 치료제 시장의 성장을 가속하는 주요 요인은?

당뇨병성 케톤산증 치료제 시장의 성장은 인슐린 의존성 당뇨병의 전 세계 유병률 증가, 급성 당뇨병 합병증으로 인한 입원율 증가, 구조화된 응급의료 프로토콜의 가용성 확대 등 여러 요인에 기인합니다. 의료 시스템은 특히 도시 지역의 병원과 응급 네트워크에서 광범위한 당뇨병 치료 노력의 일환으로 DKA 감지 및 관리 인프라에 투자하고 있습니다. 케톤체 모니터링이 일상적인 당뇨병 관리에 통합되고 SGLT2 억제제 사용자의 고혈당성 DKA와 같은 비정형 DKA 증상에 대한 인식이 높아짐에 따라 진단 및 치료 툴에 대한 수요가 증가하고 있습니다.

인슐린 전달, 포도당 및 케톤체 모니터링 장비, 중환자 치료용 첨단 수액 관리 시스템 등의 기술 혁신은 시장 성장을 더욱 지원하고 있습니다. 교육 및 홍보 활동, 인슐린 치료 접근성 개선, 맞춤형 환자 지원은 조기 개입 및 후속 조치에 대한 장벽을 낮추고 있습니다. 이와 함께 제약 및 의료기기 기업은 DKA의 재발을 예방하기 위해 고위험군 환자를 위한 통합 치료 솔루션을 개발하고 있습니다. 급성 당뇨병 합병증에 대처하기 위한 의료 정책과 디지털 기술의 연계가 진행됨에 따라 당뇨병성 케톤산증 치료제 시장은 선진국과 신흥 지역 모두에서 꾸준히 확대될 것으로 예측됩니다.

부문

치료제(인슐린 치료제, 전해질 보충 치료제, 수액 보충 치료제); 최종 사용(병원·진료소 최종 사용, 외래 수술 센터 최종 사용, 기타 최종 사용)

조사 대상 기업의 예(주목 합계 42사)

  • Abbott Laboratories
  • Akums Drugs and Pharmaceuticals
  • AstraZeneca
  • Bayer AG
  • Biocon Limited
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • Dexcom Inc.
  • Eli Lilly and Company
  • Glenmark Pharmaceuticals
  • Glytec
  • Johnson & Johnson
  • Medtronic plc
  • Merck & Co. Inc.
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Panacea Biotec
  • Pfizer Inc.
  • Sanofi S.A.
  • Wockhardt Ltd.

AI 통합

우리는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유 SLM을 조회하는 일반적인 규범을 따르는 대신에 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양 기업, 제품/서비스, 시장 데이터 등 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.07.09

Global Diabetic Ketoacidosis Market to Reach US$3.8 Billion by 2030

The global market for Diabetic Ketoacidosis estimated at US$3.1 Billion in the year 2024, is expected to reach US$3.8 Billion by 2030, growing at a CAGR of 3.4% over the analysis period 2024-2030. Insulin Therapy Treatment, one of the segments analyzed in the report, is expected to record a 2.9% CAGR and reach US$2.0 Billion by the end of the analysis period. Growth in the Electrolyte Replacement Treatment segment is estimated at 3.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$856.3 Million While China is Forecast to Grow at 6.2% CAGR

The Diabetic Ketoacidosis market in the U.S. is estimated at US$856.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$756.6 Million by the year 2030 trailing a CAGR of 6.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 2.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR.

Global Diabetic Ketoacidosis Therapeutics Market - Key Trends & Drivers Summarized

Why Is Diabetic Ketoacidosis Becoming an Increasingly Critical Focus in Diabetes Care?

Diabetic ketoacidosis (DKA) is a serious, life-threatening acute complication of diabetes mellitus, predominantly affecting patients with type 1 diabetes and, increasingly, those with poorly managed type 2 diabetes. It occurs due to insulin deficiency, leading to excessive fat breakdown, ketone production, and metabolic acidosis. DKA often arises from missed insulin doses, infections, trauma, or undiagnosed diabetes, and if untreated, can rapidly progress to coma or death. As global diabetes prevalence rises-especially among younger and underserved populations-the frequency and healthcare burden of DKA episodes are also escalating.

The growing number of insulin-dependent individuals, combined with limited access to continuous glucose monitoring and timely interventions in low- and middle-income countries, has made DKA management a high-priority focus in emergency and chronic diabetes care. Furthermore, increased use of SGLT2 inhibitors in type 2 diabetes has introduced a risk of “euglycemic DKA,” where ketoacidosis develops without significant hyperglycemia, making early detection and differentiation more challenging. This evolving risk profile is pushing providers to implement broader screening and treatment protocols in both inpatient and outpatient settings.

What Are the Key Therapeutic Strategies and Clinical Protocols for Managing DKA?

Treatment of DKA is centered on a well-established protocol involving intravenous insulin infusion, fluid resuscitation, electrolyte correction (especially potassium), and identification and resolution of the underlying trigger. Immediate administration of isotonic saline helps restore circulatory volume, while insulin therapy halts ketogenesis and gradually reduces hyperglycemia. Potassium supplementation is critical, as insulin therapy drives potassium into cells, often leading to dangerous hypokalemia if not carefully monitored. In severe cases, bicarbonate therapy may be used to correct profound acidosis, although its use is reserved for extreme pH derangements.

Rapid bedside blood ketone measurement, arterial blood gas analysis, and continuous monitoring of blood glucose and electrolyte levels are essential components of acute DKA management. Hospital emergency departments and intensive care units are typically equipped with protocols for triaging and stabilizing patients with moderate to severe DKA. Post-recovery, patients require structured insulin regimen adjustment, education on sick-day rules, and improved access to glucose monitoring to prevent recurrence. This systemic approach involves collaboration among endocrinologists, emergency care providers, diabetes educators, and critical care specialists.

How Are Technological and Diagnostic Advances Enhancing DKA Management and Prevention?

Technological innovation in diabetes care is significantly improving the early detection and management of DKA. Continuous glucose monitoring (CGM) systems, insulin pumps with auto-suspend features, and mobile apps with real-time alerts are helping patients detect metabolic changes before severe decompensation occurs. Blood ketone meters-now widely available for at-home use-enable early diagnosis during illness or insulin interruption, reducing hospital admissions and long-term complications.

Healthcare providers are increasingly utilizing predictive analytics in electronic health records to flag patients at high risk of DKA, especially during hospital admissions for infections, surgeries, or medication non-compliance. Educational platforms integrated with telehealth services are playing a growing role in preventing DKA by supporting insulin adherence, nutritional planning, and early intervention during illness. The expansion of remote diabetes care and structured discharge planning is enhancing long-term patient outcomes and reducing recurrence rates.

What Are the Key Drivers Propelling Growth in the Diabetic Ketoacidosis Therapeutics Market?

The growth in the diabetic ketoacidosis therapeutics market is driven by several factors, including the rising global prevalence of insulin-dependent diabetes, increased hospitalization rates for acute diabetic complications, and expanding availability of structured emergency care protocols. Healthcare systems are investing in DKA detection and management infrastructure as part of broader diabetes care initiatives, especially in urban hospitals and emergency networks. The integration of ketone monitoring into routine diabetes management and the growing awareness of atypical DKA presentations-such as euglycemic DKA in SGLT2 inhibitor users-are also fueling demand for diagnostic and therapeutic tools.

Market growth is further supported by innovation in insulin delivery, glucose and ketone monitoring devices, and advanced fluid management systems for critical care. Educational outreach, improved access to insulin therapy, and personalized patient support are reducing barriers to early intervention and follow-up. In parallel, pharmaceutical and device companies are developing integrated care solutions for high-risk patients to prevent recurrent DKA events. As healthcare policies and digital technologies align to address acute diabetes complications, the diabetic ketoacidosis therapeutics market is expected to expand steadily across both developed and emerging regions.

SCOPE OF STUDY:

The report analyzes the Diabetic Ketoacidosis market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment (Insulin Therapy Treatment, Electrolyte Replacement Treatment, Fluid Replacement Treatment); End-Use (Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Abbott Laboratories
  • Akums Drugs and Pharmaceuticals
  • AstraZeneca
  • Bayer AG
  • Biocon Limited
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • Dexcom Inc.
  • Eli Lilly and Company
  • Glenmark Pharmaceuticals
  • Glytec
  • Johnson & Johnson
  • Medtronic plc
  • Merck & Co. Inc.
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Panacea Biotec
  • Pfizer Inc.
  • Sanofi S.A.
  • Wockhardt Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Diabetic Ketoacidosis - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Type 1 and Uncontrolled Type 2 Diabetes Propels Risk of Diabetic Ketoacidosis (DKA)
    • Increased Hospitalization Rates for Hyperglycemic Emergencies Strengthen Demand for Acute DKA Management Protocols
    • Growing Awareness of DKA Symptoms Promotes Early Intervention and Reduces Mortality Risk
    • Expansion of Insulin Pump Therapy and CGM Use Throws the Spotlight on DKA Prevention Technologies
    • Clinical Integration of Point-of-Care Ketone Testing Devices Improves Rapid Diagnosis in Emergency Departments
    • AI-Based Glucose Monitoring Alerts Enhance Early DKA Risk Detection in Home-Care Settings
    • Adoption of Standardized Emergency DKA Protocols Across Hospitals Supports Timely Electrolyte Correction
    • Growth in Pediatric Diabetes Diagnoses Fuels Demand for Child-Specific DKA Treatment Guidelines
    • Rising Awareness Among Primary Care Physicians Supports Timely DKA Referral and Hospitalization
    • Expansion of Tele-Endocrinology Improves Access to Preventive Care in DKA-Prone Patients
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Diabetic Ketoacidosis Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Diabetic Ketoacidosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Diabetic Ketoacidosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Insulin Therapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Insulin Therapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Insulin Therapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Electrolyte Replacement Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Electrolyte Replacement Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Electrolyte Replacement Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Fluid Replacement Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Fluid Replacement Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Fluid Replacement Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Diabetic Ketoacidosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • JAPAN
    • Diabetic Ketoacidosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CHINA
    • Diabetic Ketoacidosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • EUROPE
    • Diabetic Ketoacidosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Diabetic Ketoacidosis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Diabetic Ketoacidosis by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • FRANCE
    • Diabetic Ketoacidosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • GERMANY
    • Diabetic Ketoacidosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Diabetic Ketoacidosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Diabetic Ketoacidosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Diabetic Ketoacidosis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Diabetic Ketoacidosis by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Diabetic Ketoacidosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • INDIA
    • Diabetic Ketoacidosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: India 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Diabetic Ketoacidosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Diabetic Ketoacidosis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Diabetic Ketoacidosis by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Diabetic Ketoacidosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Diabetic Ketoacidosis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Diabetic Ketoacidosis by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AFRICA
    • Diabetic Ketoacidosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제